Cempra Inc (NASDAQ:CEMP) was downgraded by Vetr from a “buy” rating to a “sell” rating in a report issued on Monday. They presently have a $4.07 target price on the stock. Vetr‘s price objective would suggest a potential downside of 3.10% from the stock’s current price.
Several other equities research analysts have also recently issued reports on the company. SunTrust Banks, Inc. cut Cempra from a “buy” rating to a “sell” rating and decreased their price objective for the stock from $18.00 to $5.00 in a report on Tuesday, December 20th. Jefferies Group LLC set a $10.00 price objective on Cempra and gave the stock a “hold” rating in a report on Monday, December 12th. Cowen and Company cut Cempra from an “outperform” rating to a “market perform” rating in a report on Monday, November 21st. Needham & Company LLC cut Cempra from a “buy” rating to a “hold” rating in a report on Wednesday, November 23rd. Finally, Cantor Fitzgerald set a $28.00 price objective on Cempra and gave the stock a “buy” rating in a report on Monday, January 2nd. Three investment analysts have rated the stock with a sell rating, twelve have given a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $11.88.
Cempra (NASDAQ:CEMP) traded up 9.09% on Monday, reaching $4.20. The company had a trading volume of 1,974,747 shares. The firm has a 50-day moving average of $3.42 and a 200-day moving average of $10.73. Cempra has a 12 month low of $2.55 and a 12 month high of $26.95. The stock’s market capitalization is $220.05 million.
Cempra (NASDAQ:CEMP) last posted its quarterly earnings data on Tuesday, February 28th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by $0.03. Cempra had a negative return on equity of 59.94% and a negative net margin of 678.72%. The business had revenue of $7.95 million for the quarter, compared to analyst estimates of $4.19 million. During the same quarter last year, the business earned ($0.48) EPS. Cempra’s revenue for the quarter was up 37.3% compared to the same quarter last year. On average, equities research analysts expect that Cempra will post ($1.17) earnings per share for the current fiscal year.
Your IP Address:
In related news, Director Dov A. Md Goldstein sold 150,000 shares of the stock in a transaction on Wednesday, March 8th. The stock was sold at an average price of $3.55, for a total value of $532,500.00. Following the transaction, the director now directly owns 95 shares of the company’s stock, valued at approximately $337.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Dov A. Md Goldstein sold 105,460 shares of the stock in a transaction on Friday, January 13th. The stock was sold at an average price of $3.40, for a total value of $358,564.00. Following the completion of the transaction, the director now directly owns 95 shares in the company, valued at $323. The disclosure for this sale can be found here. Insiders sold a total of 1,193,060 shares of company stock worth $4,088,280 over the last ninety days. Corporate insiders own 17.80% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Norges Bank purchased a new position in shares of Cempra during the fourth quarter valued at $743,000. Guggenheim Capital LLC purchased a new position in shares of Cempra during the fourth quarter valued at $560,000. Tudor Investment Corp Et Al purchased a new position in shares of Cempra during the fourth quarter valued at $598,000. Bogle Investment Management L P DE purchased a new position in shares of Cempra during the fourth quarter valued at $280,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Cempra during the fourth quarter valued at $1,711,000. 79.92% of the stock is currently owned by institutional investors and hedge funds.
Cempra Company Profile
Cempra, Inc is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections.
Receive News & Ratings for Cempra Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc and related companies with our FREE daily email newsletter.